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ABSTRACT
Objective: This study explores the correlation between the 
expression of E-cadherin, p53 tumor suppressor gene, c-erb-B2 
(HER-2/neu) and steroid receptors (ER, PgR) in invasive ductal 
breast carcinoma with axillary lymph node metastases.
Patients and Methods: We have investigated tumor samples 
from sixty patients with invasive ductal breast carcinoma.  30 of 
the patients had  axillary  lymph node metastases and 30 had no 
axillary lymph node metastases. Tumor tissues of these patients 
were evaluated by immunohistochemistry for E-cadherin, p53, 
c-erb-B2 (HER-2/neu) and steroid receptors (ER, PgR). 
Results: E-cadherin staining was  not expressed in 39 patients 
(65%) with invasive ductal breast carcinoma. ER, PgR, p53, and 
c-erb-B2 signals were positive in 36  (60%), 26 (43.3%), 33 (55%), 
and 29 (48.3%) of the patients, respectively. PgR and c-erb-B2 
expression was  associated with lymph node metastases (p=0.009, 
p=0.001, respectively). No association was found  between the 
reduced E-cadherin protein and  age. The presence of E-cadherin 
was associated with axillary lymph node metastases and p53 
(p<0.009, p<0.001, respectively). 
Conclusion: We found that,  the p53 protein may play a role 
in regulation of E-cadherin protein expression in invasive ductal 
breast carcinomas  with axillary lymph node metastases. 
Keywords: Breast carcinoma, E-cadherin, p53, c-erb-B2, ER, 
PgR, Metastases
ÖZET
Amaç: Aksiller lenf nodu metastazlı invaziv duktal meme 
karsinomda E-cadherin, p53 tümör supressör gen, c-erbB-2 (HER-
2/neu)  ve  steroid reseptörleri (ER ve PgR) ekspresyonu arasındaki 
ilişkiyi araştırmak amaçlanmıştır.
Hastalar ve Yöntem: Bu çalışmada, 30 aksiller lenf nodu 
metastazlı ve 30 aksiller lenf nodu metastazı mevcut olmayan 
invaziv duktal meme karsinomlu 60 hasta immunokimyasal 
metodu kullanılarak E-cadherin ve c-erbB-2, ER ve PgR  antikorları 
değerlendirildi.
Bulgular: İnvaziv duktal meme karsinomlu 60 hastanın 
39’unda (%65) E-cadherin ile boyanma tesbit edilmedi. Sırasıyla 
ER, PgR, p53, ve c-erb-B2, 60 hastanın 36’ında (%60), 60 hastanın 
26’ında (%43,3), 60 hastanın 33’ünde (%55), and 60 hastanın 
29’unda (%48,3) pozitif boyanma görüldü. PgR ve c-erb-B2 
boyanması lenf nodu metastazı ile ilişkili idi (sırasıyla, p=0,009, 
p=0,001). E-cadherin proteini ile yaş arasında ilişki görülmedi. 
E-cadherin ile lenf nodu metastazı ve p53 arasında ilişki görüldü 
(sırasıyla, p<0,009, p<0,001). 
Sonuç: p53 proteini E-cadherin protein ekspresyonu gösteren 
aksiller lenf nodu metastazlı invaziv duktal meme karsinomda bir 
role sahiptir.
Anahtar kelimeler: Meme karsinomu, E-cadherin, p53, c-erb-B2, 
ER, PgR Metastaz
Introduction 
Breast cancer is the most frequent cancer in women and the 
leading cause of cancer mortality in women worldwide [1-3]. 
E (epithelial)-cadherin is a 120 kDa member of a family of 
transmembrane glycoproteins and is an epithelium specific 
cell-to-cell adhesion molecule. Immunohistochemical 
(IHC) studies have shown that all normal epithelial tissues 
strongly express E-cadherin at the cell membrane. Cell 
adhesion molecules are important in the regulation of cell 
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differentiation and morphogenesis. It seems to play a crucial 
role in tumour invasion and metastasis [2,3]. In experimental 
systems cadherins decrease tumour invasions. Several 
groups have studied E-cadherin expression and its prognostic 
value in different tumour types and the down-regulation of 
E-cadherin expression in breast carcinomas has been found 
to correlate with grade of the tumor differentiation [4,5]. 
One of the best known tumor suppressor genes is the 
p53 gene. It is located on chromosome 17 and encodes for 
a nuclear phosphoprotein that binds to DNA, preventing 
progression of the cell from the G1 to the S-phase in the 
cell cycle. Many reports have shown that overexpression of 
the p53 protein may be an indicator of poor prognosis in 
breast cancer, particullary if metastases are present in the 
axillary nodes [5,6]. c-erb-B2 is amplified in approximately 
20 % of breast cancers, and HER2 gene amplification in 
breast cancer has been associated with tumor invasiveness, 
progressive regional and distant metastases, and with an 
adverse prognosis. Breast cancer is a hormone-dependent 
tumor; the expression of ER and PgR provide important 
indicator for efficacy and prognosis in patients with 
endocrine therapies [3,4,7].
In this study, we examined the patterns of E-cadherin, 
p53, c-erb-B2, ER and PgR expression in a series of 
invasive ductal breast carcinomas, with axillary  lymph node 
metastases and compared these expression patterns with the 
expression in the primary tumours.
Patients and Methods 
Material for this study was obtained from sixty samples of 
paraffin-embedded tumour tissues. 30 of the patients had 
axillary  lymph node metastases and 30 had no axillary 
lymph node metastases. The samples were analysed for 
protein expression of p53 and E-cadherin. The mean age of 
the patients was 49.5 years (range 29 to 80). 
After the review of hematoxylin and eosin (H&E)-
stained slides from each patient, a representative block was 
chosen for the the whole population.  Blocks were cut as 
4- µm-thick sections, placed on slides. 
Clinical data and pathology reports for all 60 patients 
were analyzed to identify age, grade, lymph node status, 
expression of ER and PgR, and expression of c-erb-B2 and 
p53. Histologic grading of tumors was confirmed by the 
modified Richardson and Bloom method [8]. The expression 
of E-cadherin in normal ducts, primary tumors, and in the 
corresponding axillary lymph node metastases was analyzed 
individually in each patient. One section for each patient was 
examined histologically after hematoxylin and eosin staining 
to confirm the malignancy.  Another section from each patient 
was used to examine the expression of E-cadherin. 
The distribution of clinical, histological, and prognostic 
features of the patients is shown in Table I. Routine avidin-
biotin complex IHC  techniques [8] were used for the 
assessment of all antibodies shown in Table I.  Positive and 
negative controls for each marker were used according to 
the supplier’s data sheet (DAKO, Carpinteria, CA, USA; 
Labvision/Neomarkers, CA,USA). For each tumor, IHC 
was performed for ER, PR, and HER2 on a tumor block 
from both the SF group and on a second tumor block. All 
procedures were performed in-house using the Bench Mark 
XT system (Ventana Medical Systems,Inc., Tucson, AZ, 
USA) and the iView Detection Kit (Ventana, AZ, USA). 
All steps were automated according to the Bench Mark 
XT system. The complex for each reaction was visualized 
using 3-Amino-9Ethylcarbazole (AEC), counter-stained 
with hematoxylin, and examined under a light microscope. 
Tumors were registered as showing c-erbB-2, ER, PgR 
p53 and E-cadherin overexpression if more than 10% of 
the tumor cells were positive. E-cadherin expression in the 
epidermis was used as positive control. IHC scoring was 
performed in a blind fashion. E-cadherin was observed 
at cell-cell boundaries of breast cancer cells. E-cadherin 
expression IHC was semi-quantitatively analyzed according 
to the percentage of cells showing membrane positivity: 0, 0 
to 10%; (-), 10 to 30%; 1+, 30 to 70%; 2+, > 70%.
Table I. Correlation of ER, PgR, p53 and c-erb-B2 positivity with 
lymphatic invansion.
Features LI-Positive       LI-Negative P-value*
No. of 
patients
% No. of patients %
Age >40 24 52.2 22 47.8 *p=0.542
<40 6 42.8 8 57.2
Grade I
          II
         III
4 80,0 1 20.0 **p=0.586
15 55.6 12 44.4
11 39.2 17 60.8
ER (+) 19 52.8 17 47.2 *p=0.598
(-) 11 45.9 13 54.1
PgR (+) 8 30.7 18 69.3 *p=0.009
(-) 22 64.8 12 35.2
p53 (+) 19 57.6 14 42,4 *p=0.194
(-) 11 40.8 16 59,2
c-erb-B2 (+) 21 72.5 8 27,5 *p=0.001
(-) 9 29.1 22 70.9
LI: lymphatic invasion, ER: estrogen receptor, PgR:progesterone receptor, 
*Pearson Chi-Square, **Kolmogoro-Smirnov test
101Kılınç
E-cadherin in ductal breast carcinomasMarmara Medical Journal 2015; 28: 99-104
Statistical analysis 
All statistical analyses were performed on a personal 
computer with the SPSS 11.0 PC program. To compare 
categorical variations, Pearson’s Chi-Square and the 
Kolmogorov-Smirnov tests were used. P values of p=0.05 
or less were considered statistically significant. 
Results 
The age range of these patients was 29-80 years (median, 
49.5 years) at the time of surgery. Immunostaining for 
E-cadherin appeared as cell membranous staining in tumor 
cells (Figure 1). Myoepithelial and stromal cells did not 
express E-cadherin. 
Membrane expression of E-cadherin was observed in 21 
of 60 (35%) invasive ductal breast carcinomas, and in 39 
of 60 (65%) there was a reduced expression. The  status of 
the lymph node metastases, showed a reduced expression 
of E-cadherin in 25/30 (83.3%) of patients who had lymph 
node metastases, versus in 14/30 (46.6%) without lymph 
node metastases. A reduced expression of E-cadherin has 
been found in association with the  histological  grade of 
the carcinoma,  the status of the metastases in the lymph 
nodes and the levels of p53, with  levels of    p=0.009, 
p=0.035 and p<0.001, respectively (Figure 2). There was no 
association between the E-cadherin expression and age. The 
scores for the Kolmogorov-Smirnov test relating E-cadherin 
imunoreactivity and clinicopathological features in invasive 
ductal breast carcinoma are shown in Table II. 
Figure 1. E-cadherin membranous staining in invasive ductal bre-
ast carcinoma (Immunoperoxidase, original magnification X200).
Figure 2.The presence of E-cadherin interms of the histological 
grade.
Table II. E-cadherin imunoreactivity and clinicopathological features in invasive ductal breast carsinoma.
Features E-cadherin(-) % E-cadherin(+) % E-cadherin(++) % P-value*
Age(yrs)
>40(n=46) p=1.00030 65.3 10 21.7 6 13.0
<40(n=14) 9 64.3 4 28.6 1 7.1
Histological Grade
I   (n=12) 4 33,3 4 33.3 4 33.3
II  (n=23) 17 73.9 4 17.4 2 8.7
III (n=25) 18 72.0 6 24.0 1 4.0
LI-Positive (n=30) 25 83.4 4 13.3 1 3.3
p=0.035
LI-Negative (n=30) 14 46.7 10 33.3 6 20.0
p53  (+)
p53  (-)
32 96.6 1 3.0 0 0.0
P<0.001
7 25.9 13 48.2 7 25.9
*Kolmogorov-Smirnov test, LI: lymphatic invasion
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The clinicopathologic data including age, ER, PgR, p53 and 
c-erb-B2 positivity and lymphatic invasion are shown in 
Table I. There was no correlation between the statuse of the 
axillary lymph metastases and age, histological grade, ER, 
or p53. Significant associations were observed between PgR 
and c-erb-B2 expression and the status of the axillary lymph 
metastases (p=0.009, p=0.001, respectively). p53 staining 
was always nuclear and was considered specific only when 
homogeneous. The p53 staining was positive for invasive 
ductal breast carcinomas (55%). E-cadherin staining was not 
evident  39/60 (65%) in invasive ductal breast carcinomas. 
ER, PgR, p53, and c-erb-B2 signal were positive for 36/60 
(60%), 26/60 (43.3%), 33/60 (55%), and 29/60 (48.3%) of 
patients, respectively. 
Discussion
We investigated the expression of four biological markers 
associated with prognosis of 60 invasive ductal carcinomas 
(c-erb-B2, p53, ER and PgR) and assessed the relationship 
between these markers and E-cadherin expression. In this 
study we have shown that decreased E-cadherin expression 
is frequent in breast cancer. Breast cancer is one the 
most common cancers among women. There are various 
benign and malignant breast lesions that can be difficult to 
differentiate histologically and which, therefore, can cause 
diagnostic problems. Metastasis is the most important 
cause of morbidity and mortality in this disease [1-3]. 
Axillary lymph node metastasis is one of the important 
metastatic routes of breast carcinoma. As local metastases, 
the synchronous axillary metastases may represent the 
potentially metastatic breast cancer cells much better than 
the primary tumor. 
Variable clinical outcome of patients with breast cancer 
has stimulated the search for powerful prognostic markers 
which can predict tumor behavior. Although axillary lymph 
node status still remains the most important prognostic 
factor, a long list of potential prognostic biomarkers has now 
been identified [3,7,15]. 
E-cadherin inactivation in breast cancer has been shown 
to be strongly associate with ductal breast cancer. Most of 
the previous studies have indicated that the overall survival 
and disease-free survival of the breast cancer patients had 
tumors significantly decreased  with altered E-cadherin 
expression. The effect on survival seems to be most relevant 
in axillary node negative patients and also in grade III 
ductal carcinomas of the breast. Since,  tumor grade and 
lymph node status have strong association with prognosis, it 
seems that E-cadherin expression correlates with prognosis 
of breast cancer  [1-5,10]. E-cadherin, located on the long 
arm of chromosome 16, is a cell adhesion molecule between 
epithelial cells. E-cadherin is a 120kD transmembrane 
glycoprotein. Cell adhesion molecules are important in the 
regulation of cell differentiation and morphogenesis. The 
cell adhesion molecule E-cadherin (epithelial cadherin) 
is a member of the cadherin family of transmembrane 
glycoproteins that mediate calcium dependent homophilic 
cell-cell adhesion. E-cadherin acts as an invasion suppressor 
molecule [7,11,12]. Invasion is the hallmark of malignancy. 
Half of all cancer deaths are either directly or indirectly due 
to local invasion and metastasis in distant organs. The first 
step in invasion and metastasis is the detachment of cancer 
cell from the primary tumor [12,13,15]. The E-cadherin gene 
is frequently lost or mutated in tumors. Loss of E-caderin 
expression is thought to facilitate tumor cell detachment 
from primary tumor. Reduction or loss of expression of 
either E-cadherin is associated with invasion, metastasis, 
and poor prognosis in several types of human malignancies, 
including breast cancer [13,14]. 
The p53 protein has many functions. It acts as a 
transcription factor by both transactivating some genes and 
suppressing transcription of others. The most important 
action in prevention of tumour formation and progression 
is probably the “guardian of the genome” function. Genetic 
abnormalities of the p53 tumor suppressor gene are among 
the most frequent mutations in tumorigenesis. p53 protects 
cells from DNA damage by inducing either growth arrest or 
apoptosis in response to stress signals [5,6,9].
In this study we analyzed immunohistochemically the 
expression of p53 and E-cadherin proteins in the axillary 
lymph node metastases and  assessed  the relationship 
between clinicopathologic variables. We stained the 
primary tumor using IHC  produres. Products of p53, 
E-cadherin, c-erbB-2 genes, ER, and PgR have been studied 
immunuhistochemically in 60 patients. 
The loss of hormone receptor in axillary nodal metastasis 
may partly explain why some patients with hormone 
receptor-positive primary tumors are reported to respond 
poorly to endocrine therapy [11,15,16]. 
Breast cancer is a kind of hormone-dependent tumor; 
the expression of ER receptor and PgR receptor is the 
important indicator for efficacy and prognosis in patients 
with endocrine therapies [6,7]. 
Several retrospective studies demonstrated ER, PgR, and 
HER2 status instability between primary breast cancer and 
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synchronous axillary lymph node metastases [7,16]. In this 
study, it was found that there was statistically a significant 
association between PgR status and c-erb-B2 expression and 
lymph node metastases (p=0.009, p=0.001, respectively). 
We found no significant correlation between grade, age, 
ER, and p53 expression with lymph node metastases. Yang 
et al. [17] found that expression of c-erb-B2 was positively 
correlated with the status of lymph node metastases. Our 
findings also supported the views of the Yang et al. [17] 
that lymph node meastases were corelated with c-erb-B2 
positivity. 
Cobanoglu et al. [18] and Rakha et al. [19] reported that 
no correlation was observed when comparing E-cadherin 
expression and age and lymph node status. Jeschke et al. 
[20] who found that a strong expression of E-cadherin 
in carcinoma in situ was demonstrated. Expression of 
E-cadherin was moderate in invasive carcinomas without 
metastases. However, very weak expression of E-cadherin 
in primary carcinomas with lymph node metastases was 
detected. Park et al. [1] who found an associated between 
E-cadherin and lymph node metastases. They have shown 
that abnormal E-cadherin expression in primary tumours 
with lymph node metastases is a potential prognostic factor. 
Jones et al. [21] and Hunt et al. [22] reported that a strong 
correlation between reduced membrane levels of E-cadherin 
and the presence of lymph node metastases. We also found 
similar association. Our findings suggest that reduced 
E-cadherin might play a potential role in invasive ductal 
breast carcinomas with axillary lymph node metastases. 
Evluation of E-cadherin expression in primary invasive 
breast carcinomas with axillary lymph node metastases 
seems to provide additional prognostic information [15]. 
Harigopal et al. [23] have shown that a strong E-cadherin 
expression in lymph node metastases was highly predictive 
of improved survival, whereas expression in primary 
tumours was not. 
Howard et al. [24] reported that the E-cadherin expression 
was not associated with tumor grade. Our results agree with 
those of Charpin et al. [25] and Parker et al. [26]  who found 
that reduced E-cadherin expression has been associated with 
high histological grade. The independence of E-cadherin 
expression supports the notion that it assists aggressive 
tumor growth by providing a support structure for cells to 
adhere and accelerates invasion and metastasis. 
There was an association with E-cadherin and p53 in 
our study. Howard et al. [24] did not found any relationship 
between p53 and E-cadherin expression in contrast with 
the reports by Bukholm et al. [12] and Charpin et al. [25] 
reported that the p53 protein has a role in E-cadherin protein 
expression in breast carcinomas. Hosaka et al. [27] reported 
that the general apoptosis-related proteins, p53, BcI-2 
and E-cadherin, rather than breast cancer-specific factors 
play important and cooperative roles in comedonecrosis 
formation in early invasive breast cancers [24,27].
Conclusion
In this study, we used prognostic biomarkers, age, tumor 
grade and lymph node status for prognostic purposes. Our 
study confirms that decreased expression of E-cadherin, 
p53, ER, PgR and presence of expression c-erb-B2 proteins 
are associated with agressive clinical behavior in invasive 
ductal breast carcinomas. In addition to such parameters as 
lymph node status, histologic type and grade, the hormone 
receptors, E-cadherin, p53 and c-erb-B2 of a primary 
breast carcinoma carry clinical utility in determining 
patient treatment options and overall prognosis. Validity 
of the prognostic significance of E-cadherin alteration and 
coexpression of E-cadherin and other biomarkers needs 
a prospective study on a much larger population of the 
patients.
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